

Supplementary Table 6. Bivariate Analyses Comparisons of HRQoL among Treated UC Patients by Subgroups

Subgroup		EQ VAS (n = 293)			MCS (n = 293)			PCS (n = 293)		
		No.	Mean	SD	No.	Mean	SD	No.	Mean	SD
Medication class	5-ASA mono	197	70.6	21.1	197	47.2	9.4	197	51.6	5.8
	Steroid	34	59.4	26.3	34	45.3	12.9	34	45.6	10.6
	IM/IS	14	63.2	26.8	14	40.0	12.6	14	45.3	11.3
	Biologics/JAKi	30	64.4	22.1	30	42.3	12.1	30	50.9	6.9
	Other	18	66.3	23.3	18	49.2	10.1	18	50.2	4.6
Severity of UC ^a	Mild	191	71.8	20.2	191	47.4	10.2	191	52.1	5.7
	Moderate	84	60.6	24.1	84	44.0	11.1	84	47.1	8.7
	Severe	18	63.6	28.5	18	44.3	8.9	18	48.5	7.9
Age (yr)	18–39	86	65.1	22.3	86	41.9	11.3	86	50.5	7.8
	40–64	150	67.8	23.1	150	47.1	9.6	150	51.0	6.9
	≥ 65	57	73.4	20.5	57	50.6	9.4	57	48.8	7.0
Sex	Male	163	63.8	23.3	163	45.6	10.6	163	50.2	7.0
	Female	130	73.4	20.3	130	47.1	10.3	130	50.7	7.4
Employment status	Employed	188	68.4	22.1	188	46.9	9.5	188	50.9	6.2
	Unemployed	105	67.5	23.2	105	45.1	12.0	105	49.5	8.7
Medication adherence ^b	High (≥ 80%)	176	69.9	22.2	176	47.4	10.7	176	51.2	7.0
	Low (< 80%)	34	62.4	20.1	34	42.3	9.2	34	48.6	7.6
Time since diagnosis (yr)	< 5	83	66.1	21.8	83	45.2	11.7	83	50.5	6.9
	5–14	105	71.7	20.8	105	47.0	10.1	105	51.5	6.2
	≥ 15	85	68.4	24.1	85	47.5	9.9	85	50.0	7.1

^aThe level of self-reported severity of condition when using medication.

^bThe amount of prescribed UC medication taken in the past 4 weeks.

HRQoL, health-related quality of life; UC, ulcerative colitis; EQ VAS, EuroQoL visual analog scale; MCS, mental component score; PCS, physical component score; SD; standard deviation; 5-ASA mono, 5-aminosalicylic acid monotherapy; IM/IS, immunomodulator/immunosuppressant; JAKi, Janus kinase inhibitors.